Neurocrine Biosciences Inc

NASDAQ:NBIXUnited States

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Contact Information

Headquarters

6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130

Phone

858-617-7600

Fax

858-617-7602

Executives

Non-Executive Independent Chairman of the Board

William Rastetter

President, Chief Executive Officer, Director

Kyle Gano

Chief Financial Officer

Matthew Abernethy

Chief Human Resource Officer

Julie Cooke

Chief Scientific Officer

Jude Onyia